| Literature DB >> 35071067 |
Abstract
BACKGROUND AND OBJECTIVES: Coagulase-negative staphylococci (CoNS) have emerged as a major pathogen in nosocomial meningitis. This study was designed to describe the clinical profile, laboratory parameters, treatment, and outcomes of CoNS meningitis in patients admitted to Hamad General Hospital, Qatar.Entities:
Keywords: Coagulase-negative Staphylococcus; meningitis; neurosurgical device; vancomycin
Year: 2021 PMID: 35071067 PMCID: PMC8751523 DOI: 10.4103/ajns.AJNS_144_21
Source DB: PubMed Journal: Asian J Neurosurg
Clinical and cerebrospinal fluid characteristics at the time of presentation of the involved patients
| Variable | Value, |
|---|---|
| Fever | 12 (100) |
| Cough | 7 (58.3) |
| Mental alteration | 7 (58.3) |
| Headache | 5 (41.7) |
| Vomiting | 5 (41.7) |
| Seizures | 1 (8.3) |
| Focal neurological signs | 1 (8.3) |
| Cerebrospinal fluid | |
| WBCs/mL, median (IQR) | 493.50 (193.75–613.75) |
| Neutrophils, median (IQR) | 84.8 (74.00–92.25) |
| Lymphocytes, median (IQR) | 10 (7.25–14.75) |
| Total protein (g/dl), median (IQR) | 90.5 (54.75–107.25) |
| CSF glucose (mg/dl), median (IQR) | 52.2 (30.6–66.2) |
| Positive gram stain | 12 (100) |
| Positive culture | 12 (100) |
WBCs – White blood cells; CSF – Cerebrospinal fluid; IQR – Interquartile range
Clinical characteristics, microbiological findings, treatment, and outcome of the of CoNS meningitis in our series
| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years)/sex | 32/male | 40/female | 28/male | 21/male | 38/male | 39/female | 24/male | 43/male | 56/male | 47/male | 39/male | 54/male |
| Nationality | Nepalese | Filipino | Sri Lankan | Nepalese | Bangladeshi | Indonesian | Nepalese | Nepalese | Iraqi | Jordanian | Nepalese | Cyprus |
| Infection onset after procedures (days) | 10 | 16 | 13 | 18 | 22 | 15 | 10 | 11 | 7 | 13 | 14 | |
| Underlying neurosurgical condition | ||||||||||||
| Head injury | No | Yes | No | Yes | No | No | No | No | No | No | No | No |
| Intracerebral hg | No | No | No | No | Yes | Yes | No | Yes | No | Yes | Yes | Yes |
| Brain tumor | Yes | No | No | No | No | No | No | No | No | No | No | No |
| Hydrocephalus | Yes | No | Yes | No | No | No | Yes | No | Yes | No | No | No |
| Associated | No | No | Yes | No | No | No | No | No | No | No | Yes | No |
| Infection setting | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial | Nosocomial |
| Neurosurgical device | VP shunt | EVD | VP shunt | EVD | EVD | EVD | VP shunt | EVD | VP shunt | EVD | EVD | EVD |
| Comorbidities | ||||||||||||
| Hypertension | No | Yes | No | No | Yes | Yes | No | Yes | No | Yes | Yes | Yes |
| AVM | No | No | No | No | No | No | No | No | No | No | No | No |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Antimicrobials susceptibility | ||||||||||||
| Amoxil/calv | R | R | R | S | R | R | S | ND | R | R | R | R |
| Vancomycin | S | S | S | S | S | S | S | S | S | S | S | S |
| Tazocin | R | R | R | S | R | R | S | ND | R | R | R | R |
| Linezolid | ND | ND | S | S | ND | ND | S | ND | S | S | S | ND |
| Teicoplanin | ND | S | S | S | ND | S | S | S | S | S | S | ND |
| Oxacillin | R | R | R | S | R | R | S | S | R | R | R | R |
| Ceftriaxone | R | R | R | S | R | R | ND | S | R | R | R | R |
| Empirical therapy | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Meropenem + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin | Ceftriaxone + vancomycin |
| Duration of therapy (days) | 3 | 6 | 5 | 5 | 4 | 5 | 4 | 3 | 4 | 3 | 3 | 6 |
| Definitive therapy | Vancomycin | Vancomycin | Linezolid | Cloxacillin | Vancomycin | Vancomycin | Cloxacillin | Cloxacillin | Vancomycin | Linezolid | Vancomycin | Vancomycin |
| Duration of therapy (days) | 14 | 15 | 10 | 12 | 10 | 12 | 20 | 13 | 10 | 14 | 14 | 14 |
| EVD removal | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Outcome | Cured | Cured | Cured | Cured | Cured | Cured | Cured | Cured | Cured | Cured | Cured | Cured |
R – Resistant; S – Sensitive; ND – Not done; EVD – External ventricular drain; VP – ventriculoperitoneal; S. capitis – Staphylococcus capitis; S. epidermidis – Staphylococcus epidermidis; S. haemolyticus – Staphylococcus haemolyticus; AVM – Arteriovenous malformation